Indapta Therapeutics Inc of San Francisco, US, has raised $50 million in a Series A financing round to advance its technology for allogeneic natural killer (NK) cell therapies. This involves isolating and expanding a subset of NK cells known as G-NK cells, suitable for administration with a monoclonal antibody.
Merck & Co Inc has selected Curve Therapeutics Ltd as a new partner to help it discover and validate up to five new targets for the development of drugs for oncology and neurology indications. Located in Southampton, UK, Curve has a platform technology for identifying peptides contained in libraries that exhibit specific biological activity against selected therapeutic targets. Both the library and the targets are displayed in the cytoplasm of mammalian cells.
Intellia Therapeutics Inc is to out-license rights to its ex vivo Crispr/Cas9 genome editing platform to ONK Therapeutics Ltd enabling the Irish company to develop engineered natural killer (NK) cell therapies for cancer. ONK is developing off-the-shelf NK cell therapies. In addition to the genome editing platform, ONK will also have access to the US company’s lipid nanoparticle delivery technologies. The agreement will enable the development of up to five allogeneic NK cell therapies.
Life Sciences Partners (LSP) of the Netherlands has raised an additional €150 million for its LSP 7 fund, bringing the total amount for investment up to €1 billion. This represents the final close of one of the largest venture funds in Europe. The monies will be used to invest in 15 to 20 companies which are developing new drug therapies and medical technologies, LSP said on 11 February.
Ethris GmbH has raised $26.3 million in a Series B financing round to support development of messenger RNA (mRNA) therapeutics, an area of growing interest to the pharmaceutical industry. The Munich, Germany-based company has developed a technology enabling the delivery of candidate therapies directly to the respiratory system. Whereas the small number of approved RNA medicines are delivered to patients by injection, Ethris has developed nebulisation technologies for inhaled administration.
UK-based CellCentric Ltd has secured a new investment from an arm of the American Cancer Society to progress a small molecule drug for multiple cancer indications. The investment, from BrightEdge, the cancer society’s philanthropic venture capital fund, will support clinical development of inobrodib, a candidate treatment for prostate and other cancers. Simultaneously, Morningside Investments Ltd, an existing investor, is increasing its financial support for the company. Both financing deals are equity investments, the size of which was not disclosed.
Hal Barron, the chief scientific officer at GlaxoSmithKline Plc, is to become chief executive of a new regenerative medicine company that will seek to understand the process of cellular rejuvenation with the goal of slowing or even reversing the effects of disease. The company, Altos Labs Inc, will combine basic science with translational medicine across two institutes in the US and one in the UK. It is being launched with $3 billion of start-up capital, according to a statement issued on 19 January.
Belgium-based UCB SA is to acquire a US developer of drugs for rare diseases in a move that will both expand its existing epilepsy franchise and give it access to gene therapy technology. The proposed acquisition of Zogenix Inc of Emeryville, California is valued at approximately $1.9 billion (€1.7 billion) and has been approved by the boards of directors of both companies.
Evotec SE is to collaborate with Eli Lilly and Co to discover up to five potential therapeutics for diabetes and chronic kidney diseases, leveraging its experience in metabolic disease discovery to investigate new approaches. Evotec has already worked with Novo Nordisk A/S on possible treatments for kidney diseases and has access to a kidney disease patient database to identify and validate possible drug targets. In the field of diabetes, it has a proprietary beta cell replacement therapy in preclinical development.
AstraZeneca Plc has agreed to pay $75 million initially, and up to an additional $1.5 billion in option fees and milestone payments, for rights to up to three small molecule therapeutics for cancer. The partner is Scorpion Therapeutics Inc of Boston, US, which has an integrated platform for drug discovery drawing on chemical proteomics, structure-based drug design and machine learning.